Vaxart, Inc., a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, announced that the European Patent Office (EPO) formally published the grant of European Patent No. 3791859 effective today on August 26, 2026 (European Patent Bulletin 26/35).

"Securing this patent expands our global intellectual property portfolio and secures additional protection of our norovirus asset for Europe through at least 2036," said Steven Lo, Chief Executive Officer at Vaxart. "As leaders in oral vaccine development, covering critical aspects of our proprietary delivery approach further solidifies our intellectual property estate. As the industry sees ongoing challenges with traditional injected norovirus candidates, this patent secures our potential advantage in delivering a targeted, oral tablet solution for norovirus, an area of high unmet need."

Following grant publication, the patent will be validated in key European territories, including Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom.